MCL1 and ovarian cancer: This is followed by our in vivo-based investigation revealing for the first time the effects of minocycline to reduce both plasma and tumoral IL-6 expression along with down-regulation of tumoral p-STAT3, p-ERK1/2 and MCL-1 in an experimental model of ovarian cancer in mice.